Welcome to our dedicated page for Camp4 Therapeutics SEC filings (Ticker: CAMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CAMP4 Therapeutics Corporation filings document a clinical-stage biopharmaceutical issuer focused on regulatory RNA-targeting antisense oligonucleotide therapeutics. Its 8-K reports furnish operating results, corporate presentations and program updates for CMP-002 and the company's broader regRNA mapping and ASO discovery work, while material-agreement disclosures describe research, collaboration and license arrangements tied to neurodegenerative and kidney disease targets.
Proxy materials cover board elections, auditor ratification and equity incentive plan matters. Other filings address director appointments, compensatory arrangements, stock-based compensation, capital-structure disclosures, shareholder voting matters and the company’s emerging growth company status.
Camp4 Therapeutics Corp director and Chief Executive Officer Josh Mandel-Brehm purchased 6,551 shares of common stock on August 3, 2026, at $1.65 per share. The shares were acquired in the second closing of a private placement under a Securities Purchase Agreement dated September 9, 2025, as amended August 3, 2026. Following this purchase, he directly owned 284,968 shares of Camp4 common stock.
CAMP4 Therapeutics Corporation completed the second closing of its $100 million private placement, issuing common stock and pre-funded warrants to institutional and accredited investors. This closing raised approximately $50.1 million in gross proceeds before fees.
Investors purchased 10,756,498 shares of common stock at $1.53 per share and 21,925,368 pre-funded warrants at $1.5299 each, plus 39,306 shares at $1.65 to certain directors, employees, consultants and company founders. The pre-funded warrants carry a $0.0001 per-share exercise price, are exercisable at any time, may be exercised on a cashless basis, and are subject to a beneficial ownership limitation not exceeding 19.99%. The unregistered offering relied on the Section 4(a)(2) exemption. CAMP4 plans to use net proceeds to advance its lead ASO candidate CMP-002 into a Phase 1/2 trial for SYNGAP1-related disorder, following Australian regulatory clearances, and to support earlier-stage pipeline programs.
On July 27, 2026, CAMP4 Therapeutics Corporation received clearance from Australia’s Therapeutic Goods Administration and a local Human Research Ethics Committee to begin a Phase 1/2 first‑in‑human trial of CMP‑002, its investigational therapy for SYNGAP1‑related disorder, a rare condition with no approved treatments.
This regulatory milestone satisfies conditions under CAMP4’s September 9, 2025 Securities Purchase Agreement, including the CTA Milestone, Price Threshold Waiver and Second Closing Trigger. CAMP4 is now eligible, subject to remaining closing conditions and investor participation, to receive up to approximately $50.1 million in gross proceeds from a second private placement closing in exchange for up to 32,721,172 shares of common stock or pre‑funded warrants, expected on or about August 3, 2026. CMP‑002 is an ASO candidate designed to upregulate SYNGAP1 expression by targeting regulatory RNA, supporting CAMP4’s broader strategy of developing disease‑modifying treatments for genetic disorders.
Camp4 Therapeutics Corp director Douglas E. Williams received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $4.34 per share and expire on June 9, 2036. All 28,000 underlying shares vest together on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, assuming continued service through that date.
Camp4 Therapeutics Corp director Richard A. Young reported receiving a compensation grant of stock options. He was awarded options to buy 28,000 shares of common stock at an exercise price of $4.34 per share, expiring on June 9, 2036.
The options vest in full on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, as long as he continues serving the company through that date. After this grant, he holds options for 28,000 shares directly.
Camp4 Therapeutics director and 10% owner Andrew J. Schwab reported receiving a grant of stock options representing 28,000 shares of common stock. The options have an exercise price of $4.34 per share and expire on June 9, 2036. According to the footnote, all shares underlying the option vest on the earlier of the first anniversary of the grant date or the issuer's next annual stockholder meeting, contingent on continued service. After this grant, Schwab holds 28,000 options directly.
Camp4 Therapeutics director Steven H. Holtzman received a grant of stock options for 28,000 shares of common stock. The options have an exercise price of $4.34 per share and expire on June 9, 2036. All 28,000 options vest on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting, as long as he continues serving the company through that date.
Camp4 Therapeutics Corp director Stewart Murray received a grant of stock options covering 28,000 shares of Common Stock. The options have an exercise price of $4.34 per share and expire on June 9, 2036.
The 28,000 underlying shares vest in full on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, provided Murray continues service with Camp4 Therapeutics through that vesting date. Following this grant, his directly held option position reported in this filing is 28,000 options.
Camp4 Therapeutics Corp director and 10% owner Amir Nashat received a grant of stock options for 28,000 shares of common stock. The options have an exercise price of $4.34 per share and no cash was paid at grant. They vest in full on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, as long as Nashat continues to provide service through that date. After this grant, he holds options for 28,000 shares, which expire on June 9, 2036.
CAMP4 Therapeutics Corporation reported results from its annual meeting and changes to its equity compensation programs. Stockholders approved an amendment to the 2024 Equity Incentive Plan so that any outstanding pre-funded warrants are included in the year-end share count used in the evergreen formula for annual share increases.
The board also adopted a 2026 Inducement Plan allowing various equity awards covering up to 500,000 shares of common stock, to be used as hiring inducements without separate stockholder approval under Nasdaq Listing Rule 5635(c)(4). Stockholders elected three Class II directors, ratified Ernst & Young LLP as auditor for 2026, and approved the equity plan amendment.